The field of cancer immunotherapy is red hot right now. Notably absent from the list are therapeutic cancer vaccines. Only one therapeutic agent that might be considered a vaccine has made it to market, while other once-promising vaccine candidates have failed in recent late-stage efficacy trials. Still, the data emerging from all these studies and others is helping researchers overcome some of the inherent difficulties in designing vaccines that actually work. For a look at recent developments in the field of cancer vaccines check out this article in Genetic Engineering and Biotechnology written by their Technical Editor Patricia Fitzpatrick Dimond, Ph.D.